Evaluation of analogues of furan-amidines as inhibitors of NQO2 by Alnabulsi, S. et al.
Accepted Manuscript
Evaluation of analogues of furan-amidines as inhibitors of NQO2
Soraya Alnabulsi, Buthaina Hussein, Elham Santina, Izzeddin Alsalahat,
Manikandan Kadirvel, Rachael N. Magwaza, Richard A. Bryce, Carl H.
Schwalbe, Alex G. Baldwin, Ilaria Russo, Ian J. Stratford, Sally Freeman
PII: S0960-894X(18)30204-X
DOI: https://doi.org/10.1016/j.bmcl.2018.03.025
Reference: BMCL 25679
To appear in: Bioorganic & Medicinal Chemistry Letters
Received Date: 23 January 2018
Revised Date: 8 March 2018
Accepted Date: 10 March 2018
Please cite this article as: Alnabulsi, S., Hussein, B., Santina, E., Alsalahat, I., Kadirvel, M., Magwaza, R.N., Bryce,
R.A., Schwalbe, C.H., Baldwin, A.G., Russo, I., Stratford, I.J., Freeman, S., Evaluation of analogues of furan-
amidines as inhibitors of NQO2, Bioorganic & Medicinal Chemistry Letters (2018), doi: https://doi.org/10.1016/
j.bmcl.2018.03.025
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and
review of the resulting proof before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
  
 
Bioorganic & Medicinal Chemistry Letters 
 
 
Evaluation of analogues of furan-amidines as inhibitors of NQO2 
Soraya Alnabulsi
a
, Buthaina Hussein
a
, Elham Santina
a
, Izzeddin Alsalahat
a
, Manikandan Kadirvel
a
, 
Rachael N. Magwaza
a
, Richard A. Bryce
a
, Carl H. Schwalbe
b,c
, Alex G. Baldwin
a
, Ilaria Russo
d
, Ian J. 
Stratford
a  
and Sally Freeman
a, 
aDivision of Pharmacy & Optometry, School of Health Sciences, Faculty of Biology, Medicine & Health, University of Manchester, Manchester, M13 9PT, U.K. 
bSchool of Life and Health Sciences, Aston University, Aston Triangle, Birmingham, B4 7ET, U.K. 
cCambridge Crystallographic Data Centre, 12 Union Road, Cambridge, CB2 1EZ, U.K. 
d School of Biological Sciences, Faculty of Biology, Medicine & Health, University of Manchester, Manchester, M13 9PT, U.K. 
 
——— 
 Corresponding author. Tel.: +44 (0)161 275 2366; e-mail: Sally.Freeman@manchester.ac.uk 
NRH: quinone oxidoreductase 2 (NQO2) is a cytosolic 
flavoprotein enzyme [1] widely distributed in human heart, brain, 
lung, liver and skeletal muscle [2]. NQO2 is a potential target for 
cancer chemotherapy as its inhibition has therapeutic and/or 
preventative potential. In our laboratory, non-symmetrical furan-
amidine 1 (Figure 1) and para-substituted analogues were 
identified as novel lead inhibitors of NQO2 with both anti-cancer 
and anti-malarial activities [3]. Here, further modifications to 
these non-symmetrical furan-amidines have been evaluated. 
Some of the non-symmetrical furan-amidines [3] showed poor 
water solubility, therefore the furan ring of 1 was replaced by 
more water-soluble isosteric heterocycles, including imidazole 
and oxazole. The lead NQO2 furan inhibitor possesses the highly 
basic amidine group, which will potentially decrease its passive 
diffusion and oral bioavailability [4, 5]. Here, analogues of the 
non-symmetrical furan-amidine 1 were synthesized in which the 
amidine group was isosterically replaced with less basic groups: 
imidate, N-aryl amidine (reversed amidine), N-aryl amide and 
amidoxime groups. From the initial virtual screening study, one 
of the first reported potent NQO2 inhibitors was the symmetrical 
3,4-dimethyl-substituted furan-amidine 2 (Figure 1) with an IC50 
of 50 nM [6]. Given the structurally similarity of compounds 1
 
 
Figure 1. Structures of the non-symmetrical furan-amidine 1, the symmetrical 3,4-dimethylfuran-amidine 2 and the proposed 4-methylfuran-amidine 3. 
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Inhibitors of the enzyme NQO2 (NRH: quinone oxidoreductase 2) are of potential use in cancer 
chemotherapy and malaria. We have previously reported that non-symmetrical furan amidines 
are potent inhibitors of NQO2 and here novel analogues are evaluated. The furan ring has been 
changed to other heterocycles (imidazole, N-methylimidazole, oxazole, thiophene) and the 
amidine group has been replaced with imidate, reversed amidine, N-arylamide and amidoxime to 
probe NQO2 activity, improve solubility and decrease basicity of the lead furan amidine. All 
compounds were fully characterised spectroscopically and the structure of the unexpected 
product N-hydroxy-4-(5-methyl-4-phenylfuran-2-yl)benzamidine was established by X-ray 
crystallography. The analogues were evaluated for inhibition of NQO2, which showed lower 
activity than the lead furan amidine. The observed structure-activity relationship for the furan-
amidine series with NQO2 was rationalized by preliminary molecular docking and binding mode 
analysis. In addition, the oxazole-amidine analogue inhibited the growth of Plasmodium 
falciparum with an IC50 value of 0.3 M. 
© 2018 Elsevier Ltd. All rights reserved. 
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Scheme 1. Synthesis of 4-(4-phenyl-1H-imidazol-2-yl)benzamidine acetate 4; 
Reagents and conditions: (i) NH4OAc, MeOH, rt. (ii) NH2OH.HCl, t-BuOK, 
dry DMSO, 0 °C - rt; (iii) HCO2NH4, Pd/C, AcOH, reflux; (iv) HCl(g), abs. 
EtOH, CHCl3, 0 °C- rt; (v) NH4OAc, Abs. EtOH, rt, 12 hr. 
 
Scheme 2. Synthetic pathway for 4-(1-methyl-4-phenyl-1H-imidazol-2-
yl)benzamidine 9; Reagents and conditions: (i) CH3I, KOH, acetone, rt. (ii) 
NH2OH.HCl, t-BuOK, dry DMSO, 0 °C - rt; (iii) HCO2NH4, Pd/C, AcOH, 
reflux. 
 
and 2, it is of interest to assess the activity of non-symmetrical 4-
methylfuran-amidine analogue 3 (Figure 1) as an NQO2 
inhibitor, the synthesis of which is attempted in this study. 
In order to enhance the aqueous solubility of furan amidine 1 
(clogS -1.81, 4.0 mg/ml [8]), the furan ring was first replaced 
with an imidazole group to give 4 (clogS -1.27, 13.9 mg/ml [8]). 
The synthesis of imidazole-amidine 4 is shown in Scheme 1. 4-
(4-Phenyl-1H-imidazol-2-yl)benzonitrile 7 was synthesized by 
the reaction of 4-cyanobenzaldehyde 5 with phenylglyoxal 
monohydrate 6 in the presence of ammonium acetate (Scheme 1) 
[9]. Attempts to convert the nitrile 7 directly into amidine 4 using 
the Pinner synthesis (Scheme 1, steps iv and v) failed because of 
the basicity of the nitrogen of the imidazole ring (pKa 6.9), 
causing precipitation of 7 as the hydrochloride salt. Therefore the 
aryl nitrile 7 was reacted with hydroxylamine to give the 
amidoxime  intermediate 8 [5], which was reduced to the amidine 
4 using ammonium formate [10]  (Scheme 1) [11]. 
The N-methylimidazole analogue 9 was synthesized from the 
reaction of nitrile 7 with methyl iodide (Scheme 2) giving the 
possibility of the formation of two regioisomers 10 or 11. The 
NOESY spectrum confirmed the formation of the least hindered 
regioisomer 10 (see Figure S1) which showed a long-range 
interaction between the N-methyl protons and H-5’. 4-(1-Methyl-
4-phenyl-1H-imidazol-2-yl)benzamidine 9 was synthesized from 
10 through the formation of amidoxime 12 (Scheme 2).  
The oxazole-amidine 13 (clogS -1.30, 13.3 mg/ml [8]) was 
synthesized as shown in Scheme 3. The key precursor 4-cyano-
N-(2-oxo-2-phenylethyl)benzamide 16 was prepared from the 
coupling between 4-cyanobenzoyl chloride 14 and 2-amino-1-
phenylethanone hydrochloride 15, in the presence of sodium 
bicarbonate [12]. In the presence of acetic anhydride/conc. 
sulfuric acid, the benzamide 16 readily cyclised to give 4-(5- 
phenyloxazol-2-yl)benzonitrile 17 [13, 14], which was converted 
to the oxazole-amidine 13 through the formation of the 
amidoxime intermediate 18 (Scheme 3). 
The thiophene-amidine 19 (clogS -2.25, 1.57 mg/ml [8]) was 
also synthesised (Scheme 4) as a more lipophilic isostere of the 
furan-amidine 1 (clogS -1.81, 4.03 mg/ml [8])). The synthesis of 
19 first required the Paal-Knorr synthesis of 2,5-diarylthiophene 
21 from the reaction between the 1,4-diketone 20 [3] and 
Lawesson’s reagent.  The conversion of the nitrile group of 21 to 
the amidine 19 was via the amidoxime intermediate 22. 
Reduction of the amidoxime 22 to the amidine 19 was attempted 
by heating at reflux in acetic acid in the presence of ammonium 
formate and Pd. Only starting material 22 was recovered, which 
was attributed to poisoning of the Pd catalyst by the thiophene. 
The reduction of 22 to amidine 19 was therefore achieved using 
triethylsilane as hydrogen donor in the presence of palladium (II) 
chloride catalyst (Scheme 4) [15]. 
To address the high basicity of the amidine group, several less 
basic isosteres of 1 were synthesized in which the amidine group 
was replaced with methyl imidate 23, amidoxime 24, N-aryl 
amidines (reversed amidines) 25-26 and N-aryl amide 27-29. pKa 
and clogS are given in Table 1 and clogP and solubilities (mg/ml) 
are given in SI for the key compounds, with the non-amidine 
analogues being less basic, potentially enhancing passive 
permeability. The syntheses of these analogues are illustrated in 
Schemes 5 and 6. It was anticipated that heating of ethyl 
benzimidate hydrochloride 30 (prepared by reaction of nitrile 31 
with ethanol) [3] at reflux with ammonium chloride 
methanol/water would give the furan-amidine 1, however the 
isolated product was the methyl imidate 23 [16] (Scheme 5). The 
methyl imidate group is a much less basic isostere (pKa 6.2) [16] 
than the highly basic amidine group (pKa 11.8) [17]. 
 
 
Scheme 3. Synthesis of 4-(5-phenyloxazol-2-yl)benzamidine acetate 13; Reagents and conditions: (i) NaHCO3, DCM, 0 °C – rt; (ii) Ac2O, conc. H2SO4, rt; (iii) 
NH2OH.HCl, t-BuOK, dry DMSO, 0 °C - rt; (iv) HCOONH4, Pd/C, AcOH, reflux. 
  
 
 
Scheme 4. Synthesis of the non-symmetrical 4-(5-phenylthiophen-2-
yl)benzamidine acetate 19; Reagents and conditions: (i) 60 °C, Lawesson’s 
reagent; (ii) NH2OH.HCl, t-BuOK, dry DMSO, 0 °C - rt; (iii) (Et)3SiH, PdCl2, 
AcOH, Ac2O, rt - reflux. 
 
Scheme 5. Syntheses of methyl 4-(5-phenylfuran-2-yl)benzimidate 
hydrochloride 23 and N-hydroxy-4-(5-phenylfuran-2-yl)benzamidine 24 from 
nitrile 31; Reagents and conditions: i-EtOH, ii- NH4Cl, MeOH/ H2O, reflux.; 
iii- NH2OH. HCl, t-BuOK, dry DMSO, 0 °C - rt. 
 
Scheme 6. Synthesis of N-aryl amidines (reversed amidines) 25-26 and N-aryl amides 27-29; Reagents and conditions: i- HCl(g), CHCl3, 0 °C – rt; (ii) 
Lawesson’s reagent, THF, 55 °C; (iii) NaBH4, CuSO4, EtOH, 0 °C – rt; (iv) AcCl, dry CH3CN, rt; (v) S-2-naphthylmethyl thioacetimidate hydrobromide, AcOH, 
CHCl3, rt. 
 
An isosteric analogue of the asymmetric furan-amidine 1 with 
an amidoxime group 24 was synthesized as a less basic isostere 
(pKa 5-6) for the furan amidine [18]. In addition, the amidoxime 
group is a known prodrug for the amidine group and can enhance 
oral bioavailability of amidine-containing drugs [4, 5] which is 
activated through reduction of the amidoxime group by human 
liver microsomes [19]. N-Hydroxy-4-(5-phenylfuran-2-
yl)benzamidine 24 was synthesized by the reaction of nitrile 31 
with hydroxylamine (Scheme 5). 
The first step in the syntheses of the reverse amidine and 
amide analogues 25-29 was the preparation of the key 1,4-
diketone intermediates 32 and 33 [3] (Scheme 6). The cyclization 
of the 1,4-diketones 32, 33 into furans 34, 35 and thiophenes 36, 
37 were catalysed by dry hydrogen chloride gas and Lawesson’s 
reagent, respectively. The nitro-groups in the intermediates 34-37 
were reduced to amines 38-41 using sodium borohydride in the 
presence of catalytic copper sulfate [20]. The reduction of the 
nitro-groups into amines was confirmed by upfield shift of the 
protons on the aromatic ring: The peaks of the H-2’, H-4’, H-5’ 
and H-6’ protons of 34 were shifted up-field from 8.57, 8.12, 
7.59 and 8.05 ppm to 6.87, 6.52, 7.08 and 6.94 ppm in 38, 
respectively (Figure S2). The N-aryl amidines 25 and 26 were 
synthesized from the reaction of the amines 39 and 41, 
respectively, with S-2-naphthylmethyl thioacetimidate 
hydrobromide (Scheme 6) [21-23]. The furan N-aryl amides 27 
and 28 and N-(3-(5-phenylthiophen-2-yl)phenyl)acetamide 29 
were synthesized from the reaction of acetyl chloride with amines 
38, 39 and 40, respectively (Scheme 6). 
The synthesis of the 3-methylfuran-amidine analogue 3 was 
attempted as shown in Scheme 7, however coupling of 4-
cyanophenyl methyl ketone 42 and α-bromomethyl phenyl 
ketone 43 failed to give the diaryl mono-methyl 1,4-diketone 44. 
Diketone 44 would have cyclised to give furan 45, a precursor for 
amidine 3. Instead, the condensation of 42 and 43 led to the 
formation of 5-methyl-2,4-diarylfuran nitrile 46. The structure 
was confirmed by X-ray crystallography of its amidoxime 
derivative 47, the ORTEP diagram of which is shown in Figure 
2, annotated with the numbering scheme adopted. Further
  
 
 
Scheme 7. Synthetic pathway for the preparation of furan-amidine 48; Reagents and conditions: (i) EtMgBr, Et2NH, dry THF, 0 °C – rt; (ii) HCl(g), abs. EtOH, 
CHCl3, 0 °C- rt; (iii) NH4OAc, Abs. EtOH, rt; (iv) NH2OH. HCl, t-BuOK, dry DMSO, 0 °C – rt.; (v) NH4 formate, Pd/C. 
 
Figure 2. ORTEP diagram for the amidoxime derivative 47. 
 
 
Scheme 8. Proposed mechanism for the formation of furan nitrile 46. 
 
detailed crystallographic discussion of compound 47 can be 
found in Supplementary Material. A proposed mechanism for the 
formation of nitrile 46 is shown in Scheme 8. The amidoxime 47 
was then converted to the amidine 48 for evaluation as an NQO2 
inhibitor. 
The ability of the synthesized compounds to inhibit the 
enzymatic activity of NQO2 was determined by a 
spectrophotometric method that monitored the decolouration of 
the blue redox dye 2,6-dichlorophenolindophenol (DCPIP) (pH 
7.4). The rate of decolouration of DCPIP is indicative of NQO2 
activity [3]. 
The isosteric replacement of furan ring 1 into imidazole 4, N-
methylimidazole 9, oxazole 13 and thiophene 19 led to an 
increase of the IC50 values when compared with 1 (Table 1).  
The isosteric replacement of amidine group 1 by methyl 
imidate 23, amidoxime 24, N-aryl amidines (reversed amidines) 
25-26 and para-N-aryl amide 28 all led to the loss of NQO2 
inhibitory activity (Table 1). The meta-N-aryl amides 27 and 29 
showed moderate NQO2 inhibitory activity with IC50 values of 
approximately 1 and 2 M, respectively. It should be noted that 
as the assay is performed at physiological pH, the amidine group 
is protonated. On the other hand, imidate 23 will be present as 
both the protonated and neutral forms since the pKa of the 
conjugate acid is estimated to be 6.7. 
In order to provide insight into the observed SAR, the 
synthesized NQO2 inhibitors were then computationally docked 
into the NQO2 active site using the X-ray crystal structure of 
human NQO2 with bound FAD (PDB code 1QR2; resolution of 
2.1 Å) [24]. This was performed via the GOLD 5.1 docking 
software (CCDC, Cambridge, UK) with the ChemScore scoring 
function [25]. The ten top-scoring poses were saved and those 
with a steric clash term exceeding 6 kJ/mol were omitted.  
Our prior in silico prediction of the NQO2-bound poses of a 
set of asymmetric furan-amidine compounds, including 
compound 1,[3] found that  stacking interactions between 
ligands and NQO2 were a common feature, formed by the ligand 
aromatic rings with the isoalloxazine ring of FAD in particular, 
but also with other aromatic residues such as Phe178’ and 
Phe126’. Secondly, the bound ligand poses were found to fall 
into three basic types [3], depending on the hydrogen bonding 
interaction of their amidine group with rather distinct regions of 
the active site: with Gln122 (pose I), with Asn161’ (pose II) or 
with Thr71 (pose III). 
As for this previous work, the binding geometries of 
asymmetric furan-, imidazole-, N-methylimidazole- and 
thiophene-amidines predicted here fit well in the deep NQO2 
pocket and form a range of  stacking interactions. Furan-
amidine 1, the experimentally most potent NQO2 inhibitor, is 
  
Table 1. cLogP, pKa, IC50 (± SE) for the inhibition of NQO2 and IC50 (± SE) 
for the inhibition of growth of Plasmodium falciparum by the non-
symmetrical analogues of the lead furan-amidine 1. 
Compound cLogS
a 
pKa
a,b 
IC50 NQO2 
(μM)  SE 
IC50 Pf 
(μM)  SE 
1 -1.81 11.1 0.068  0.009 1.5  0.002 
4 -1.27 11.2 1.111  0.005 5.3  0.001 
9 -0.75 11.2 Inactive
c 
NT
d 
13 -1.30 10.8 Inactive
c
 0.31  0.001 
19 -2.25 11.3 0.773  0.004 18.9  0.002 
23 -5.64 6.7 Inactive
c
 NT
d
 
24 -5.02 8.7 Inactive
c
 NT
d
 
25 -3.42 9.5 Inactive
c
 0.77  0.002 
26 -3.87 9.6 Inactive
c
 0.97  0.001 
27 -5.34 - 1.14 (n=1) NT
d
 
28 -5.34 - Inactive
c
 NT
d
 
29 -5.90 - 2.00 (n=1) NT
d
 
48 -1.98 11.1 Inactive
c
 NT
d
 
Resveratrol -3.09 - 0.913  0.023 NT
d
 
DB75 [3,27] 0.00 11.42 
 
0.035±0.0008  
 
 
0.00050.000
2 
aCalculated using ChemAxon’s Chemicalize program [8]. 
b
pKa of the conjugate acid of the strongest basic group. 
cInactive at 10 μM. 
d
NT – not tested. 
predicted to adopt only pose I (magenta, Figure 3), forming a 
strong hydrogen bond between the amidine group and Gln122 
sidechain and nearby sidechain of Glu193. For imidazole-
amidine compound 4 (gold, Figure 3) and N-methylimidazole-
amidine 9 (cyan, Figure 3), pose I structures are preferred and 
superimpose well with 1. The N-methyl group of compound 9 
points into the active site, slightly displacing the ligand outwards 
from the bracing Trp105 (Figure S8). For thiophene-amidine 19, 
pose I (Figure 3) and pose III orientations (Figure S9) are 
predicted. For the latter, the amidine group hydrogen bonds to the 
sidechain OH of Thr71 and the backbone carbonyl of Asp117, 
although this pose possesses a relatively high active site clash 
energy, of 5.2 kJ/mol, as compared with pose I (1.9 kJ/mol). 
Therefore despite predicting a preference for pose I for 
compounds 1, 4, 9 and 19, these results are unlikely to explain 
the observed differences in their inhibitory activity. Nevertheless, 
subtle changes in electrostatic and steric interactions associated 
with the O to S substitution may be at play in determining the 
overall difference in experimental potency for compounds 1 and 
19. 
The malaria parasite Plasmodium falciparum has an enzyme 
that has a similar activity to NQO2, PfNDH2 [26], therefore 
some of the analogues were also tested against Plasmodium 
(Table 1). The oxazole-amidine 13 (IC50 0.3 M) was more 
active than the furan 1, imidazole 4 and thiophene 19 analogues. 
The reverse amidine analogues 25 and 26, which were not active 
as NQO2 inhibitors, both showed sub-micromolar IC50 activities 
in the Plasmodium parasite assay, indicating the intrinsic 
difference between the actual targets in human and in parasites. 
In conclusion, novel heterocyclic derivatives (e.g. imidazole, 
oxazole and thiophene) with a range of side chains (e.g. imidate, 
N-aryl amide, amidoxime) were designed to enhance the drug-
like properties (improved aqueous solubility and decreased 
basicity) of the lead furan-amidine 1. Most of the synthesized 
analogues showed decreased or loss of activity as NQO2 
inhibitors, when compared with 1, however these results provide 
an insight into the SAR. The inactive amidoxime 24 is of interest 
 
 
Figure 3. (A) Docked pose I of compounds 1 (magenta), 4 (gold), 9 (cyan) 
and 19 (pink) in NQO2 active site for. Distances in Å; in parentheses for 
distances involving 19.  
 
as a potential pro-drug for the non-symmetric furan-amidine 1. 
The oxazole-amidine 13 is the most active in the preliminary 
Plasmodium falciparum screen, showing a different SAR, 
promising therapeutic index against human cells and with 
mechanism of action studies on-going. 
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